{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:09:54Z","timestamp":1793650194595,"version":"4.5.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T00:00:00Z","timestamp":1516060800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"IZKF Promotionskolleg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00262-018-2117-0","type":"journal-article","created":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T01:59:03Z","timestamp":1516067943000},"page":"653-662","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1259-5825","authenticated-orcid":false,"given":"Lucas","family":"Basler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Kowalczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariola","family":"Fotin-Mleczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savas","family":"Tsitsekidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan M.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,16]]},"reference":[{"key":"2117_CR1","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0140-6736(96)91015-6","volume":"347","author":"MB Sporn","year":"1996","unstructured":"Sporn MB (1996) The war on cancer. Lancet 347:1377\u20131381","journal-title":"Lancet"},{"key":"2117_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1749-6632.1997.tb48599.x","volume":"833","author":"MB Sporn","year":"1997","unstructured":"Sporn MB (1997) The war on cancer: a review. Ann N Y Acad Sci 833:137\u2013146","journal-title":"Ann N Y Acad Sci"},{"key":"2117_CR3","first-page":"293","volume":"1796","author":"TR Geiger","year":"2009","unstructured":"Geiger TR, Peeper DS (2009) Metastasis mechanisms. Biochim Biophys Acta 1796:293\u2013308","journal-title":"Biochim Biophys Acta"},{"key":"2117_CR4","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1158\/1078-0432.CCR-16-0049","volume":"22","author":"TL Whiteside","year":"2016","unstructured":"Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I (2016) Emerging opportunities and challenges in cancer immunotherapy. Clin Cancer Res 22:1845\u20131855","journal-title":"Clin Cancer Res"},{"key":"2117_CR5","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1146\/annurev.immunol.18.1.767","volume":"18","author":"J Banchereau","year":"2000","unstructured":"Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ et al (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767\u2013811","journal-title":"Annu Rev Immunol"},{"key":"2117_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1006\/scbi.2001.0400","volume":"12","author":"AP Vicari","year":"2002","unstructured":"Vicari AP, Caux C, Trinchieri G (2002) Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 12:33\u201342","journal-title":"Semin Cancer Biol"},{"key":"2117_CR7","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S et al (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096\u20131103","journal-title":"Nat Med"},{"key":"2117_CR8","first-page":"1860","volume":"63","author":"JJ Kobie","year":"2003","unstructured":"Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, Whitesell LJ et al (2003) Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 63:1860\u20131864","journal-title":"Cancer Res"},{"key":"2117_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.immuni.2008.08.004","volume":"29","author":"CJ Melief","year":"2008","unstructured":"Melief CJ (2008) Cancer immunotherapy by dendritic cells. Immunity 29:372\u2013383","journal-title":"Immunity"},{"key":"2117_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.coi.2007.02.004","volume":"19","author":"HY Wang","year":"2007","unstructured":"Wang HY, Wang RF (2007) Regulatory T cells and cancer. Curr Opin Immunol 19:217\u2013223","journal-title":"Curr Opin Immunol"},{"key":"2117_CR11","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1002\/1097-0142(20001215)89:12<2646::AID-CNCR18>3.0.CO;2-A","volume":"89","author":"PL Triozzi","year":"2000","unstructured":"Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, Jaynes S (2000) Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 89:2646\u20132654","journal-title":"Cancer"},{"key":"2117_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1189\/jlb.0306180","volume":"81","author":"D Yang","year":"2007","unstructured":"Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ (2007) High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 81:59\u201366","journal-title":"J Leukoc Biol"},{"key":"2117_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1071059","volume":"296","author":"P Matzinger","year":"2002","unstructured":"Matzinger P (2002) The danger model: a renewed sense of self. Science 296:301\u2013305","journal-title":"Science"},{"key":"2117_CR14","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.4049\/jimmunol.176.9.5153","volume":"176","author":"N Sanchez-Sanchez","year":"2006","unstructured":"Sanchez-Sanchez N, Riol-Blanco L, Rodriguez-Fernandez JL (2006) The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J Immunol 176:5153\u20135159","journal-title":"J Immunol"},{"key":"2117_CR15","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","volume":"58","author":"S Demaria","year":"2004","unstructured":"Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L et al (2004) Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58:862\u2013870","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2117_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1367-5931(99)80014-3","volume":"3","author":"EC Jonathan","year":"1999","unstructured":"Jonathan EC, Bernhard EJ, McKenna WG (1999) How does radiation kill cells? Curr Opin Chem Biol 3:77\u201383","journal-title":"Curr Opin Chem Biol"},{"key":"2117_CR17","first-page":"307","volume":"19","author":"H Matsumoto","year":"1999","unstructured":"Matsumoto H, Takahashi T, Mitsuhashi N, Higuch K, Niibe H (1999) Modification of tumor-associated antigen (CEA) expression of human lung cancer cells by irradiation, either alone or in combination with interferon-gamma. Anticancer Res 19:307\u2013311","journal-title":"Anticancer Res"},{"key":"2117_CR18","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1002\/1097-0142(19910501)67:9<2269::AID-CNCR2820670910>3.0.CO;2-Z","volume":"67","author":"M Hareyama","year":"1991","unstructured":"Hareyama M, Imai K, Kubo K, Takahashi H, Koshiba H, Hinoda Y et al (1991) Effect of radiation on the expression of carcinoembryonic antigen of human gastric adenocarcinoma cells. Cancer 67:2269\u20132274","journal-title":"Cancer"},{"key":"2117_CR19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ijc.1018","volume":"96","author":"S Kunala","year":"2001","unstructured":"Kunala S, Macklis RM (2001) Ionizing radiation induces CD20 surface expression on human B cells. Int J Cancer 96:178\u2013181","journal-title":"Int J Cancer"},{"key":"2117_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.21037\/atm.2016.10.09","volume":"4","author":"T Bhattacharyya","year":"2016","unstructured":"Bhattacharyya T, Purushothaman K, Puthiyottil SS, Bhattacharjee A, Muttah G (2016) Immunological interactions in radiotherapy-opening a new window of opportunity. Ann Transl Med 4:51","journal-title":"Ann Transl Med"},{"key":"2117_CR21","doi-asserted-by":"publisher","first-page":"e1046028","DOI":"10.1080\/2162402X.2015.1046028","volume":"4","author":"RA Chandra","year":"2015","unstructured":"Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA et al (2015) A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 4:e1046028","journal-title":"Oncoimmunology"},{"key":"2117_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925\u2013931","journal-title":"N Engl J Med"},{"key":"2117_CR23","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2174\/092986712800099811","volume":"19","author":"B Frey","year":"2012","unstructured":"Frey B, Rubner Y, Wunderlich R, Weiss EM, Pockley AG, Fietkau R et al (2012) Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies. Curr Med Chem 19:1751\u20131764","journal-title":"Curr Med Chem"},{"key":"2117_CR24","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1470-2045(15)00054-6","volume":"16","author":"EB Golden","year":"2015","unstructured":"Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M et al (2015) Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol 16:795\u2013803","journal-title":"Lancet Oncol"},{"key":"2117_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2326-6066.CIR-13-0115","volume":"1","author":"EB Golden","year":"2013","unstructured":"Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC (2013) An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 1:365\u2013372","journal-title":"Cancer Immunol Res"},{"key":"2117_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1667\/RR13500.1","volume":"182","author":"S Demaria","year":"2014","unstructured":"Demaria S, Pilones KA, Vanpouille-Box C, Golden EB, Formenti SC (2014) The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. Radiat Res 182:170\u2013181","journal-title":"Radiat Res"},{"key":"2117_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2013.09.018","volume":"356","author":"S Siva","year":"2015","unstructured":"Siva S, MacManus MP, Martin RF, Martin OA (2015) Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett 356:82\u201390","journal-title":"Cancer Lett"},{"key":"2117_CR28","doi-asserted-by":"publisher","first-page":"e28780","DOI":"10.4161\/onci.28780","volume":"3","author":"AM Grimaldi","year":"2014","unstructured":"Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V et al (2014) Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 3:e28780","journal-title":"Oncoimmunology"},{"key":"2117_CR29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","volume":"41","author":"K Reynders","year":"2015","unstructured":"Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D (2015) The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 41:503\u2013510","journal-title":"Cancer Treat Rev"},{"key":"2117_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0b013e3181f7dbe8","volume":"34","author":"M Fotin-Mleczek","year":"2011","unstructured":"Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkic-Zrna S, Probst J et al (2011) Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34:1\u201315","journal-title":"J Immunother"},{"key":"2117_CR31","doi-asserted-by":"publisher","first-page":"627","DOI":"10.4161\/rna.8.4.15394","volume":"8","author":"C Lorenz","year":"2011","unstructured":"Lorenz C, Fotin-Mleczek M, Roth G, Becker C, Dam TC, Verdurmen WP et al (2011) Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol 8:627\u2013636","journal-title":"RNA Biol"},{"key":"2117_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jnci\/djs629","volume":"105","author":"SC Formenti","year":"2013","unstructured":"Formenti SC, Demaria S (2013) Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 105:256\u2013265","journal-title":"J Natl Cancer Inst"},{"key":"2117_CR33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/1748-717X-9-180","volume":"9","author":"M Fotin-Mleczek","year":"2014","unstructured":"Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Kowalczyk A, Kallen KJ et al (2014) mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat Oncol 9:180","journal-title":"Radiat Oncol"},{"key":"2117_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/jnci\/53.1.111","volume":"53","author":"RB Whitney","year":"1974","unstructured":"Whitney RB, Levy JG, Smith AG (1974) Influence of tumor size and surgical resection on cell-mediated immunity in mice. J Natl Cancer Inst 53:111\u2013116","journal-title":"J Natl Cancer Inst"},{"key":"2117_CR35","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/eji.200324181","volume":"34","author":"F Ghiringhelli","year":"2004","unstructured":"Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C et al (2004) CD4 + CD25 + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34:336\u2013344","journal-title":"Eur J Immunol"},{"key":"2117_CR36","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.3747\/co.v18i3.783","volume":"18","author":"JL Gulley","year":"2011","unstructured":"Gulley JL, Madan RA, Schlom J (2011) Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol 18:e150\u2013e157","journal-title":"Curr Oncol"},{"key":"2117_CR37","first-page":"5","volume":"32","author":"JE-S Richard Wayne Joseph","year":"2014","unstructured":"Richard Wayne Joseph JE-S, Jedd D, Wolchok AM, Joshua A, Ribas F, Anderson KM, Gangadhar TC, Hodi S, Hamid O, Robert C, Daud A, Hwu W-J, Kefford R, Hersey P, Weber JS, Patnaik A, De Alwis DP, Perrone AM, Kang SP, Ebbinghaus S (2014) Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol 32:5 (Abstract)","journal-title":"J Clin Oncol"},{"key":"2117_CR38","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC et al (2009) Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15:5379\u20135388","journal-title":"Clin Cancer Res"},{"key":"2117_CR39","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR et al (2014) Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124:687\u2013695","journal-title":"J Clin Invest"},{"key":"2117_CR40","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E et al (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:373\u2013377","journal-title":"Nature"},{"key":"2117_CR41","doi-asserted-by":"publisher","first-page":"e0171559","DOI":"10.1371\/journal.pone.0171559","volume":"12","author":"R Marconi","year":"2017","unstructured":"Marconi R, Strolin S, Bossi G, Strigari L (2017) A meta-analysis of the abscopal effect in preclinical models: Is the biologically effective dose a relevant physical trigger? PLoS One 12:e0171559","journal-title":"PLoS One"},{"key":"2117_CR42","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ et al (2017) DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun 8:15618","journal-title":"Nat Commun"},{"key":"2117_CR43","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3109\/09553002.2013.756595","volume":"89","author":"S Ma","year":"2013","unstructured":"Ma S, Kong B, Liu B, Liu X (2013) Biological effects of low-dose radiation from computed tomography scanning. Int J Radiat Biol 89:326\u2013333","journal-title":"Int J Radiat Biol"},{"key":"2117_CR44","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00262-017-1993-z","volume":"66","author":"MK Janiak","year":"2017","unstructured":"Janiak MK, Wincenciak M, Cheda A, Nowosielska EM, Calabrese EJ (2017) Cancer immunotherapy: how low-level ionizing radiation can play a key role. Cancer Immunol Immunother 66:819\u2013932","journal-title":"Cancer Immunol Immunother"},{"key":"2117_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ctro.2016.12.006","volume":"2","author":"F Eckert","year":"2017","unstructured":"Eckert F, Gaipl US, Niedermann G, Hettich M, Schilbach K, Huber SM et al (2017) Beyond checkpoint inhibition\u2014immunotherapeutical strategies in combination with radiation. Clin Trans Radiat Oncol 2:29\u201335","journal-title":"Clin Trans Radiat Oncol"},{"key":"2117_CR46","doi-asserted-by":"publisher","first-page":"e1323161","DOI":"10.1080\/2162402X.2017.1323161","volume":"6","author":"F Eckert","year":"2017","unstructured":"Eckert F, Jelas I, Oehme M, Huber SM, Sonntag K, Welker C et al (2017) Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo. Oncoimmunology 6:e1323161","journal-title":"Oncoimmunology"},{"key":"2117_CR47","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.4049\/jimmunol.180.5.3132","volume":"180","author":"AA Lugade","year":"2008","unstructured":"Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM (2008) Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 180:3132\u20133139","journal-title":"J Immunol"},{"key":"2117_CR48","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.4049\/jimmunol.181.5.3099","volume":"181","author":"S Matsumura","year":"2008","unstructured":"Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO et al (2008) Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 181:3099\u20133107","journal-title":"J Immunol"},{"key":"2117_CR49","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1667\/RR1860.1","volume":"173","author":"S Matsumura","year":"2010","unstructured":"Matsumura S, Demaria S (2010) Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat Res 173:418\u2013425","journal-title":"Radiat Res"},{"key":"2117_CR50","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMra052723","volume":"354","author":"IF Charo","year":"2006","unstructured":"Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:610\u2013621","journal-title":"N Engl J Med"},{"key":"2117_CR51","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fimmu.2017.00229","volume":"8","author":"E Wennerberg","year":"2017","unstructured":"Wennerberg E, Lhuillier C, Vanpouille-Box C, Pilones KA, Garcia-Martinez E, Rudqvist NP et al (2017) Barriers to radiation-induced in situ tumor vaccination. Front Immunol 8:229","journal-title":"Front Immunol"},{"key":"2117_CR52","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1016\/j.vaccine.2015.05.105","volume":"33","author":"C Vanpouille-Box","year":"2015","unstructured":"Vanpouille-Box C, Pilones KA, Wennerberg E, Formenti SC, Demaria S (2015) In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine 33:7415\u20137422","journal-title":"Vaccine"},{"key":"2117_CR53","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.1158\/0008-5472.CAN-16-0549","volume":"76","author":"ME Rodriguez-Ruiz","year":"2016","unstructured":"Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL et al (2016) Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming. Cancer Res 76:5994\u20136005","journal-title":"Cancer Res"},{"key":"2117_CR54","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3109\/07357907.2012.762780","volume":"31","author":"S Yovino","year":"2013","unstructured":"Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E (2013) The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest 31:140\u2013144","journal-title":"Cancer Invest"},{"key":"2117_CR55","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00018-015-2003-2","volume":"73","author":"C Carl","year":"2016","unstructured":"Carl C, Flindt A, Hartmann J, Dahlke M, Rades D, Dunst J et al (2016) Ionizing radiation induces a motile phenotype in human carcinoma cells in vitro through hyperactivation of the TGF-beta signaling pathway. Cell Mol Life Sci 73:427\u2013443","journal-title":"Cell Mol Life Sci"},{"key":"2117_CR56","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejca.2016.03.067","volume":"62","author":"A Levy","year":"2016","unstructured":"Levy A, Chargari C, Marabelle A, Perfettini JL, Magne N, Deutsch E (2016) Can immunostimulatory agents enhance the abscopal effect of radiotherapy? Eur J Cancer 62:36\u201345","journal-title":"Eur J Cancer"},{"key":"2117_CR57","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1158\/1078-0432.CCR-07-4462","volume":"14","author":"D Schaue","year":"2008","unstructured":"Schaue D, Comin-Anduix B, Ribas A, Zhang L, Goodglick L, Sayre JW et al (2008) T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res 14:4883\u20134890","journal-title":"Clin Cancer Res"},{"key":"2117_CR58","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-06-1772","volume":"13","author":"NJ Nesslinger","year":"2007","unstructured":"Nesslinger NJ, Sahota RA, Stone B, Johnson K, Chima N, King C et al (2007) Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 13:1493\u20131502","journal-title":"Clin Cancer Res"},{"key":"2117_CR59","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","volume":"13","author":"DN Khalil","year":"2016","unstructured":"Khalil DN, Smith EL, Brentjens RJ, Wolchok JD (2016) The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 13:273\u201390","journal-title":"Nat Rev Clin Oncol"},{"key":"2117_CR60","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","volume":"14","author":"S Farkona","year":"2016","unstructured":"Farkona S, Diamandis EP, Blasutig IM (2016) Cancer immunotherapy: the beginning of the end of cancer? BMC Med 14:73","journal-title":"BMC Med"},{"key":"2117_CR61","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/annonc\/mdx442","volume":"28","author":"AK Salama","year":"2017","unstructured":"Salama AK, Moschos SJ (2017) Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. Ann Oncol 28:57\u201374","journal-title":"Ann Oncol"},{"key":"2117_CR62","doi-asserted-by":"publisher","first-page":"p29","DOI":"10.1016\/j.ctro.2016.12.006","volume":"2","author":"F Eckert","year":"2017","unstructured":"Eckert F, Gaipl US, Niedermann G, Hettich M, Schilbach K, Huber SM et al (2017) Beyond checkpoint inhibition\u2014Immunotherapeutical strategies in combination with radiation. Clin Trans Radiat Oncol 2:p29\u201335","journal-title":"Clin Trans Radiat Oncol"},{"key":"2117_CR63","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/annonc\/mdv209","volume":"26","author":"L Apetoh","year":"2015","unstructured":"Apetoh L, Ladoire S, Coukos G, Ghiringhelli F (2015) Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol 26:1813\u20131823","journal-title":"Ann Oncol"},{"key":"2117_CR64","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1186\/1471-2407-14-748","volume":"14","author":"M Sebastian","year":"2014","unstructured":"Sebastian M, Papachristofilou A, Weiss C, Fruh M, Cathomas R, Hilbe W et al (2014) Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 14:748","journal-title":"BMC Cancer"},{"key":"2117_CR65","doi-asserted-by":"publisher","first-page":"794528","DOI":"10.1155\/2015\/794528","volume":"2015","author":"MA McNamara","year":"2015","unstructured":"McNamara MA, Nair SK, Holl EK (2015) RNA-based vaccines in cancer immunotherapy. J Immunol Res 2015:794528","journal-title":"J Immunol Res"},{"key":"2117_CR66","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-3-319-42934-2_5","volume":"209","author":"K Fiedler","year":"2016","unstructured":"Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R (2016) mRNA cancer vaccines. Recent Results Cancer Res 209:61\u201385","journal-title":"Recent Results Cancer Res"},{"key":"2117_CR67","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","volume":"17","author":"CJ Langer","year":"2016","unstructured":"Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF et al (2016) Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17:1497\u2013508","journal-title":"Lancet Oncol"},{"key":"2117_CR68","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00262-017-2000-4","volume":"66","author":"G Deplanque","year":"2017","unstructured":"Deplanque G, Shabafrouz K, Obeid M (2017) Can local radiotherapy and IL-12 synergise to overcome the immunosuppressive tumor microenvironment and allow \u201cin situ tumor vaccination\u201d? Cancer Immunol Immunother 66:833\u2013840","journal-title":"Cancer Immunol Immunother"},{"key":"2117_CR69","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ijrobp.2011.09.049","volume":"83","author":"D Schaue","year":"2012","unstructured":"Schaue D, Ratikan JA, Iwamoto KS, McBride WH (2012) Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 83:1306\u20131310","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2117_CR70","first-page":"153","volume":"2","author":"S Demaria","year":"2012","unstructured":"Demaria S, Formenti SC (2012) Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol 2:153","journal-title":"Front Oncol"},{"key":"2117_CR71","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.canlet.2013.09.015","volume":"356","author":"F Rodel","year":"2015","unstructured":"Rodel F, Frey B, Multhoff G, Gaipl U (2015) Contribution of the immune system to bystander and non-targeted effects of ionizing radiation. Cancer Lett 356:105\u2013113","journal-title":"Cancer Lett"},{"key":"2117_CR72","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2217\/imt.14.38","volume":"6","author":"US Gaipl","year":"2014","unstructured":"Gaipl US, Multhoff G, Scheithauer H, Lauber K, Hehlgans S, Frey B et al (2014) Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy. Immunotherapy 6:597\u2013610","journal-title":"Immunotherapy"},{"key":"2117_CR73","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4049\/jimmunol.150.2.353","volume":"150","author":"G Prete Del","year":"1993","unstructured":"Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S (1993) Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 150:353\u2013360","journal-title":"J Immunol"},{"key":"2117_CR74","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1074-7613(00)80165-X","volume":"12","author":"A Zlotnik","year":"2000","unstructured":"Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12:121\u2013127","journal-title":"Immunity"},{"key":"2117_CR75","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","volume":"172","author":"J Mestas","year":"2004","unstructured":"Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172:2731\u20132738","journal-title":"J Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2117-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2117-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2117-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T09:15:55Z","timestamp":1693473355000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2117-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,16]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["2117"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2117-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,16]]},"assertion":[{"value":"17 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Aleksandra Kowalczyk, Regina Heidenreich, and Mariola Fotin-Mleczek were employees of CureVac AG at the time of the experiments\u2019 performance or preparation of the manuscript. The others authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving animals were in accordance with the animal protection laws and regulations, and were approved by the local authorities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}